Mersana Therapeutics Profit Margin

Mersana Therapeutics (MRSN) currently reports a profit margin of -211.21% as of September 2025. That compares with -214.19% in the prior-year period — up 1.4% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Mersana Therapeutics's profit margin history and peer comparisons.

Mersana Therapeutics's profit margin increased from -214.19% to -211.21% — a 1.4% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mersana Therapeutics's profit margin of -211.21% is lower than the Healthcare sector average of 13.89%. That is roughly 1620.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Mersana Therapeutics's current -211.21% should be judged against Healthcare norms (sector average: 13.89%) and against MRSN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -211.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Mersana Therapeutics, and consider following MRSN for alerts when major investors trade the stock.